(463 days)
Not Found
No
The device description and performance studies focus on the physical properties and antimicrobial release of the pouch, with no mention of AI or ML.
Yes
The device is intended to securely hold a pacemaker or defibrillator and contains antimicrobial agents to reduce infection, which directly contributes to the therapeutic outcome of the implanted devices.
No
Explanation: The device is intended to securely hold a pacemaker or defibrillator and contains antimicrobial agents to reduce infection. It is not mentioned anywhere that it is used to diagnose any disease or condition.
No
The device description clearly states it is a "dual component (resorbable and non-resorbable), sterile prosthesis" constructed of "knitted filaments of polypropylene" and coated with a "bioresorbable polyarylate polymer." This describes a physical, implantable hardware device, not software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. They are used to provide information for diagnosis, monitoring, or screening.
- AIGISRx Function: The description of AIGISRx clearly states its purpose is to "securely hold a pacemaker pulse generator or defibrillator in order to create a stable environment when implanted in the body." It also contains antimicrobial agents to reduce infection in vivo (within the living body) after implantation.
- Lack of In Vitro Testing for Diagnosis: While the performance studies mention in vitro antimicrobial activity testing, this is a test of the device's properties, not a diagnostic test performed on a patient sample to diagnose a condition. The primary function and intended use are related to supporting an implanted medical device and preventing infection in vivo.
Therefore, AIGISRx is a medical device intended for implantation and not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
AIGISRx is intended to securely hold a pacemaker pulse generator or defibrillator in order to create a stable environment when implanted in the body. AIGISRX contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection in an in-vivo model of bacterial challenge following surgical implantation of the generator or defibrillator. This device is only intended to be used in conjunction with pacemakers and implantable defibrillators.
Product codes
FTL
Device Description
AIGISRX is a dual component (resorbable and non-resorbable), sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. AIGISRX is constructed of knitted filaments of polypropylene that are coated with a bioresorbable polyarylate polymer. AIGISRX bioresorbable polymer coating contains the antimicrobial agents, rifampin and minocycline in concentrations of 86 ug/cm2.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
AIGISpx is constructed of knitted filaments of polypropylene that are coated with a bioresorbable polyarylate polymer. The purpose of the resorbable coating is to act as a carrier for the antimicrobial agents. Once placed, the polymer resorbs in approximately 140 days leaving a light-weight permanent mesh incorporated into the tissue.
AIGISRX releases the antimicrobial agents, rifampin and minocycline for a minimum of 7 days to reduce the risk of infection of the implanted pulse generator following surgery. In in vitro studies, AIGISRX demonstrated antimicrobial activity against Methicillin Resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter baumanii. Enterobacter aerogenes and Proteus mirabilis.
AIGISRX™ also demonstrated in vivo effectiveness in reducing infections in a series of studies in which a pulse generator canister placed into a AIGISRX™ pouch and generator canister alone (Control) were implanted into appropriate models of infectivity (dogs or rabbits). Both AIGISRY™ and the controls were inoculated and observed for a minimum of 7 days to validate the presence of infection in the animals. The bacteria tested included Staph aureus, Staph epidermidis, Acinetobacter baumanii, and E coli which represent a majority of the infections reported in pacemaker-related endocarditis. It should be noted that the in vitro and in vivo activity of the AIGISR antimicrobials is variable against non-epidermidis strains of coagulase-negative staphylococci
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.3300 Surgical mesh.
(a)
Identification. Surgical mesh is a metallic or polymeric screen intended to be implanted to reinforce soft tissue or bone where weakness exists. Examples of surgical mesh are metallic and polymeric mesh for hernia repair, and acetabular and cement restrictor mesh used during orthopedic surgery.(b)
Classification. Class II.
0
TYRX PHARMA INC.
January 14, 2008
SECTION 5. 510(K) SUMMARY
JAN 16 2008
510(K) SUMMARY (AS REQUIRED BY 21 CFR 807.92)
Pursuant to Section 12, Part (a)(i)3A of the Safe Medical Devices Act of 1990, TyRx Pharma, Inc. is providing a summary of the safety and effectiveness information available for TyRx AIGIS,xx" Anti-bacterial Envelope, as well as the substantial equivalence decision making process used for TyRx AIGISRX™ Anti-bacterial Envelope.
Sponsor/Applicant Name and Address: TyRx Pharma, Inc. 1 Deer Park Drive, Suite G Monmouth Junction, NJ 08852
Sponsor Contact Information: Mark Citron Vice President, Clinical and Regulatory Affairs Phone: 732-246-8676 Fax: 732-246-8677 E-mail: mark@tyrxpharma.com
Date of Preparaton of 510(k) Summary: January 14, 2008
New Device Trade/Proprietary Name: AIGISRX" Anti-bacterial Envelope
Device Common/Classification Name: Bag, Polymeric Mesh, Pacemaker
Predicate Devices Name and 510(k) Numbers:
- . Bard Parsonnet Pacemaker Pouch (Listing Number 2212754)
- Pivit AB (TyRx Antimicrobial Mesh) (K053656) .
- OrthoGuard AB Antimicrobial Sleeve (K012198) .
Device Description
AIGISRX is a dual component (resorbable and non-resorbable), sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. AIGISRX is constructed of knitted filaments of polypropylene that are coated with a bioresorbable polyarylate polymer. AIGISRX bioresorbable polymer coating contains the antimicrobial agents, rifampin and minocycline in concentrations of 86 ug/cm2.
Device Intended Use:
1
3
ind 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . create a stable environment when implanted in the body. AIGISRX contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection in an in-vivo model of bacterial challenge following surgical implantation of the generator or defibrillator. This device is only intended to be used in conjunction with pacemakers and implantable defibrillators.
Performance Data:
AIGISpx is constructed of knitted filaments of polypropylene that are coated with a bioresorbable polyarylate polymer. The purpose of the resorbable coating is to act as a carrier for the antimicrobial agents. Once placed, the polymer resorbs in approximately 140 days leaving a light-weight permanent mesh incorporated into the tissue.
AIGISRX releases the antimicrobial agents, rifampin and minocycline for a minimum of 7 days to reduce the risk of infection of the implanted pulse generator following surgery. In in vitro studies, AIGISRX demonstrated antimicrobial activity against Methicillin Resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter baumanii. Enterobacter aerogenes and Proteus mirabilis.
AIGISRX™ also demonstrated in vivo effectiveness in reducing infections in a series of studies in which a pulse generator canister placed into a AIGISRX™ pouch and generator canister alone (Control) were implanted into appropriate models of infectivity (dogs or rabbits). Both AIGISRY™ and the controls were inoculated and observed for a minimum of 7 days to validate the presence of infection in the animals. The bacteria tested included Staph aureus, Staph epidermidis, Acinetobacter baumanii, and E coli which represent a majority of the infections reported in pacemaker-related endocarditis. It should be noted that the in vitro and in vivo activity of the AIGISR antimicrobials is variable against non-epidermidis strains of coagulase-negative staphylococci
Conclusions:
Based on the 510(k) summaries (21 CFR 807) and the information provided herein, we conclude that the new device is substantially equivalent to the Predicate Devices under the Federal Food Drug and Cosmetic Act.
2
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JAN 1 6 2008
TyRx Pharma, Inc. c/o Mr. Mark Citron Vice President 1 Deer Park Drive Monmouth Junction, NJ 08852
Re: K063091 AIGISRX Anti-Bacterial Envelope Regulation Number: 21 CFR 878.3300 Regulation Name: Polymeric Surgical Mesh Regulatory Class: II Product Code: FTL Dated: January 3. 2008 Received: January 4, 2008
Dear Mr. Citron:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2 – Mr. Mark Citron
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Blymmmon for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
1. INDICATIONS FOR USE STATEMENT
Page 1 of 1
| 510(k) Number (if known): | K063091 |
|---|---|
| --------------------------- | --------- |
Device Name: AIGISRXTM Anti-Bacterial Envelope
INDICATIONS/CONTRAINDICATIONS:
INDICATIONS FOR USE
AIGISRx is intended to securely hold a pacemaker pulse generator or defibrillator in order to create a stable environment when implanted in the body. AIGISRX contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection in an in-vivo model of bacterial challenge following surgical implantation of the generator or defibrillator. This device is only intended to be used in conjunction with pacemakers and implantable defibrillators.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Conpungente
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Cardiovascular Devices
510(k) Number K063091
OR
Prescription Use (Per 21 CFR 801.109)
Over-The-Counter Use